Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
Syndax's Revuforj (revumenib) won the 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases, a top honor in biopharmaceutical innovation. Revuforj is the first and only FDA-approved menin inhibitor for relapsed/refractory NPM1-mutated AML and KMT2A-translocated acute leukemia in adults and children one year and older.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.